<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38285646</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-4683</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Cardiology in review</Title><ISOAbbreviation>Cardiol Rev</ISOAbbreviation></Journal><ArticleTitle>The Impact of Long COVID-19 on the Cardiovascular System.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CRD.0000000000000654</ELocationID><Abstract><AbstractText>Long coronavirus disease (COVID) is the development or persistence of symptoms after an acute SARS-CoV-2 (COVID-19) infection. Fewer patients are developing acute COVID-19 infections, but patients with long COVID continue to have alarming long-term sequelae. Many cardiac magnetic resonance imaging studies show significant changes in cardiac structure after a COVID-19 infection, suggestive of an increased burden of many cardiovascular diseases, notably myocarditis. The pathophysiology of COVID-19 requires viral binding to angiotensin-converting enzyme 2 protein receptors throughout the body, which are upregulated by inflammation. Consequently, the numerous preexisting conditions that worsen or prolong inflammation enhance this binding and have differing effects on patients based on their unique immune systems. These pathophysiological changes drive long COVID cardiac sequelae such as inappropriate sinus tachycardia, postural orthostatic tachycardia, and other types of orthostatic intolerance. Increased screening for long COVID and low-risk interventions such as exercise regimens could alleviate the suffering endured by patients with long COVID. Many studies such as the Researching COVID to Enhance Recovery Initiative (RECOVER) trials at the National Institutes of Health are exploring potential treatments for long COVID patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMaster</LastName><ForeName>Matthew W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>From the Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Subo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fishkin</LastName><ForeName>Tzvi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Frishman</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Aronow</LastName><ForeName>Wilbert S</ForeName><Initials>WS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiol Rev</MedlineTA><NlmUniqueID>9304686</NlmUniqueID><ISSNLinking>1061-5377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Disclosure: The authors have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>19</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>19</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38285646</ArticleId><ArticleId IdType="doi">10.1097/CRD.0000000000000654</ArticleId><ArticleId IdType="pii">00045415-990000000-00198</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization website. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed November 30, 2023.</Citation></Reference><Reference><Citation>Lee TC, Murthy S, Del Corpo O, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:1203&#x2013;1210.</Citation></Reference><Reference><Citation>Johns M, George S, Taburyanskaya M, et al. A review of the evidence for corticosteroids in COVID-19. J Pharm Pract. 2022;35:626&#x2013;637.</Citation></Reference><Reference><Citation>Garcia-Lledo A, Gomez-Pavon J, Gonzalez del Castillo T, et al. Pharmacological treatment of COVID-19: an opinion paper. Rev Esp Quimioter. 2022;35:115&#x2013;130.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or Post-COVID conditions. December 26, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed March 23, 2023.</Citation></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.</Citation></Reference><Reference><Citation>Raman B, Bluemke D, Luscher TF, et al. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;11:1157&#x2013;1172.</Citation></Reference><Reference><Citation>Saurabh M, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;2:194&#x2013;202.</Citation></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135.</Citation></Reference><Reference><Citation>Chadda KR, Blakey EE, Huang C, et al. Long COVID-19 and postural orthostatic tachycardia syndrome- is dysautonomia to be blamed? Front Cardiovasc Med. 2022;9:860198.</Citation></Reference><Reference><Citation>National Institutes of Health website. Long COVID. March 16, 2022. Available at: https://covid19.nih.gov/covid-19-topics/long-covid. Accessed March 23, 2023.</Citation></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation></Reference><Reference><Citation>Tenforde MW, Kim S, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. Morb Mortal Wkly Rep. 2020;30:993&#x2013;998.</Citation></Reference><Reference><Citation>Hanson SW, Abbatfati C, Aerts J, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;16:1604&#x2013;16015.</Citation></Reference><Reference><Citation>Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. Office for National Statistics; 2023. Available at: ons.gov.uk. Accessed August 7, 2023.</Citation></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z.Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590.</Citation></Reference><Reference><Citation>Puntmann VO, Martin S, Shchendrygina A, et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022;28:2117&#x2013;2123.</Citation></Reference><Reference><Citation>Palmisano A, Vignale D, Bruno E, et al. Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis [published online ahead of print, December 21, 2022]. J Clin Ultrasound. 2023;51:613&#x2013;621.</Citation></Reference><Reference><Citation>Arany&#xf3; J, Bazan V, Llad&#xf3;s G, et al. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Sci Rep. 2022;12:298.</Citation></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, et al. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790.</Citation></Reference><Reference><Citation>Kellman P, Arai AE, Xue H. T1 extracellular volume mapping in the heart: estimation of error maps and the influence on noise precision. J Cardiovasc Magn Reson. 2013;15:56.</Citation></Reference><Reference><Citation>Li H, Zhu H, Yang Z, et al. Tissue characterization by mapping and strain cardiac MRI to evaluate myocardial inflammation in fulminant myocarditis. J Magn Reson Imaging. 2020;3:930&#x2013;938.</Citation></Reference><Reference><Citation>Puntmann VO, Valbuena S, Hinojar R, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I-analytical validation and clinical qualification. J Magn Reson Imaging. 2018;20:1&#x2013;23.</Citation></Reference><Reference><Citation>Vermes E, Carbone I, Friedrich MG, et al. Patterns of myocardial late enhancement: typical and atypical features. Arch Cardiovasc Dis. 2012;105:300&#x2013;308.</Citation></Reference><Reference><Citation>Gr&#xe4;ni C, Eichhorn C, Bi&#xe8;re L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70:1964&#x2013;1976.</Citation></Reference><Reference><Citation>Zorzi A, Perazzolo Marra M, Rigato I, et al. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol. 2016;9:e004229.</Citation></Reference><Reference><Citation>Pan JA, Lee YJ, Salerno M. Diagnostic performance of extracellular volume, native T1, and T2 mapping versus Lake Louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis. Circ Cardiovasc Imaging. 2018;11:11.</Citation></Reference><Reference><Citation>Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol. 2021;6:1078&#x2013;1081.</Citation></Reference><Reference><Citation>Mangold S, Kramer U, Franzen E, et al. Detection of cardiovascular disease in elite athletes using cardiac magnetic resonance imaging. Rofo. 2013;185:1167&#x2013;1174.</Citation></Reference><Reference><Citation>Hoffman M, Kleine-weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.</Citation></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus a first step in understanding SARS pathogenesis. J Pathol. 2004;203:631&#x2013;637.</Citation></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259&#x2013;260.</Citation></Reference><Reference><Citation>Perez-Bermejo JA, Kang S, Rockwood SJ, et al. SARS-Cov-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients. Sci Transl Med. 2021;13:eabf7872.</Citation></Reference><Reference><Citation>Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22:911&#x2013;915.</Citation></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142:68&#x2013;78.</Citation></Reference><Reference><Citation>Siripanthon B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17:1463&#x2013;1471.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802&#x2013;810.</Citation></Reference><Reference><Citation>Porzionato A, Emmi A, Barbon S, et al. Sympathetic activation: a potential link between comorbidities and COVID-19. FEBS J. 2020;287:3681&#x2013;3688.</Citation></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. 2022;225:2155&#x2013;2162.</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216.</Citation></Reference><Reference><Citation>Gunning WT, Kvale H, Kramer PM, et al. Postural orthostatic tachycardia syndrome is associated with elevated G-protein coupled receptor autoantibodies. J Am Heart Assoc. 2019;8:e013602.</Citation></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation></Reference><Reference><Citation>Cabral-Marques O, Moll G, Catar R, et al. Autoantibodies targeting G protein-coupled receptors: an evolving history in autoimmunity. Report of the 4th international symposium. Autoimmun Rev. 2023;22:103310.</Citation></Reference><Reference><Citation>Miglis MG, Seliger J, Shaik R, et al. A case series of cutaneous phosphorylated &#x3b1;-synuclein in long-COVID POTS. Clin Auton Res. 2022;32:209&#x2013;212.</Citation></Reference><Reference><Citation>Raj SR, Arnold AC, Barboi A, et al.; American Autonomic Society. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021;31:365&#x2013;368.</Citation></Reference><Reference><Citation>Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31:385&#x2013;394.</Citation></Reference><Reference><Citation>Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69:205&#x2013;211.</Citation></Reference><Reference><Citation>Jamal SM, Landers DB, Hollenberg SM, et al. Prospective evaluation of autonomic dysfunction in post-acute sequela of COVID-19. J Am Coll Cardiol. 2022;79:2325&#x2013;2330.</Citation></Reference><Reference><Citation>Buoite Stella A, Furlanis G, Frezza NA, et al. Autonomic dysfunction in post-COVID patients with and without neurological symptoms: a prospective multidomain observational study. J Neurol. 2022;269:587&#x2013;596.</Citation></Reference><Reference><Citation>Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013;61:793&#x2013;801.</Citation></Reference><Reference><Citation>Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258.</Citation></Reference><Reference><Citation>Jarczok MN, Weimer K, Braun C, et al. Heart rate variability in the prediction of mortality: a systematic review and meta-analysis of healthy and patient populations. Neurosci Biobehav Rev. 2022;143:104907.</Citation></Reference><Reference><Citation>Olshansky B, Cannom D, Fedorowski A, et al. Postural orthostatic tachycardia syndrome (POTS): a critical assessment. Prog Cardiovasc Dis. 2020;63:263&#x2013;270.</Citation></Reference><Reference><Citation>George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13:943&#x2013;950.</Citation></Reference><Reference><Citation>Fu Q, Vangundy TB, Shibata S, et al. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58:167&#x2013;175.</Citation></Reference><Reference><Citation>Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007;9:1202.</Citation></Reference><Reference><Citation>Ruzieh M, Dasa O, Pacenta A, et al. Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am J Ther. 2017;24:157161.</Citation></Reference><Reference><Citation>National Institutes of Health. COVID 19 Research. Available at: https://covid19.nih.gov/news-and-stories/nih-launches-clinical-trials-long-covid-treatments.</Citation></Reference><Reference><Citation>Hulscher N, Procter BC, Wynn C, et al. Clinical approach to post-acute sequelae after COVID-19 infection and vaccination. Cureus. 2023;15:11.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>